latamoxef 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, oxacefalosporanic acid derivatives | 1851 | 64952-97-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 4 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 76 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 54.89 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 85 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.17 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.72 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.39 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.90 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA | LILLY |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01DD06 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| CHEBI has role | CHEBI:36047 | antibacterial drugs |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.92 | acidic |
| pKa2 | 7.41 | acidic |
| pKa3 | 9.82 | acidic |
| pKa4 | 13.92 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Peptidoglycan synthase FtsI | Enzyme | INHIBITOR | IC50 | 5.94 | WOMBAT-PK | CHEMBL | |||
| Penicillin-binding protein 1A | Enzyme | INHIBITOR | IC50 | 6.72 | WOMBAT-PK | CHEMBL | |||
| Penicillin-binding protein 1B | Enzyme | INHIBITOR | IC50 | 4.64 | WOMBAT-PK | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017540 | VUID |
| N0000179709 | NUI |
| D02198 | KEGG_DRUG |
| 4017540 | VANDF |
| 4019847 | VANDF |
| C0026651 | UMLSCUI |
| CHEBI:599928 | CHEBI |
| MXL | PDB_CHEM_ID |
| CHEMBL74632 | ChEMBL_ID |
| CHEMBL1200357 | ChEMBL_ID |
| DB04570 | DRUGBANK_ID |
| 12031 | IUPHAR_LIGAND_ID |
| 64953-12-4 | SECONDARY_CAS_RN |
| 47499 | PUBCHEM_CID |
| 258330 | RXNORM |
| 002806 | NDDF |
| 004889 | NDDF |
| 350135006 | SNOMEDCT_US |
| 387099009 | SNOMEDCT_US |
| 387259002 | SNOMEDCT_US |
| D009070 | MESH_DESCRIPTOR_UI |
| 4880 | INN_ID |
| VUF6C936Z3 | UNII |
Pharmaceutical products:
None